The trial was designed to assess the safety and effectiveness of the company’s Combo Dual Therapy Stent compared to the Taxus Liberte paclitaxel-eluting stent in patients with ischemic heart disease due to a stenotic lesion located in a native coronary artery.

The trial evaluated patients with in-stent late lumen loss at nine months post-procedure.

The Combo Dual Therapy Stent utilizes the company’s patented endothelial progenitor cell (EPC) capture technology which attracts EPCs circulating in the blood to the device and forms an endothelial layer and provides protection against thrombosis and modulates restenosis.